LENSAR Inc Net Assets
LENSAR Inc net assets. Based on the latest financial reports, LENSAR Inc (LNSR) has net assets worth $14.90 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($69.56 Million) and total liabilities ($54.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore LNSR net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $14.90 Million |
| % of Total Assets | 21.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | -147.41% |
| 10-Year Change | N/A |
| Growth Volatility | 89.85 |
Net Assets of LENSAR Inc (2018–2025)
Net assets of LENSAR Inc from 2018 to 2025. This chart illustrates how LENSAR Inc's net assets have evolved over time, based on quarterly financial data. See LENSAR Inc (LNSR) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for LENSAR Inc (2018–2025)
The table below shows the annual net assets of LENSAR Inc from 2018 to 2025. For live market cap and overall valuation, see LENSAR Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-26.02 Million | -239.54% |
| 2024-12-31 | $18.65 Million | -60.48% |
| 2023-12-31 | $47.18 Million | +12.37% |
| 2022-12-31 | $41.98 Million | -23.50% |
| 2021-12-31 | $54.88 Million | -18.35% |
| 2020-12-31 | $67.21 Million | +319.98% |
| 2019-12-31 | $-30.55 Million | -49.29% |
| 2018-12-31 | $-20.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LENSAR Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15404700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
LENSAR Inc Net Assets Breakdown (December 2025)
LENSAR Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $120.00K | % |
| Other Comprehensive Income | $4.00K | % |
| Other Components | $151.43 Million | % |
| Total Equity | $-26.02 Million | 100.00% |
LENSAR Inc Competitors by Market Cap
The table below lists competitors of LENSAR Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dynamic Medical Technologies
TWO:4138
|
$68.44 Million |
|
Zakłady Lentex SA
WAR:LTX
|
$68.46 Million |
|
Taiwan Alpha Electronic Co Ltd
TWO:6204
|
$68.49 Million |
|
Sumeeko Industries Co Ltd
TWO:2066
|
$68.50 Million |
|
Shanghai Lingang Holdings Co Ltd B
SHG:900928
|
$68.40 Million |
|
Thai Mitsuwa Public Company Limited
BK:TMW
|
$68.40 Million |
|
Unitronics
TA:UNIT
|
$68.39 Million |
|
Aero Win Technology Corp
TW:8222
|
$68.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LENSAR Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 18,646,000 to -26,019,000, a change of -44,665,000 (-239.5%).
- Net loss of 34,280,000 reduced equity.
- Share repurchases of 590,000 reduced equity.
- New share issuances of 93,000 increased equity.
- Other comprehensive income decreased equity by 2,000.
- Other factors decreased equity by 9,886,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-34.28 Million | -131.75% |
| Share Repurchases | $590.00K | -2.27% |
| Share Issuances | $93.00K | +0.36% |
| Other Comprehensive Income | $-2.00K | -0.01% |
| Other Changes | $-9.89 Million | -38.0% |
| Total Change | $- | -239.54% |
Book Value vs Market Value Analysis
This analysis compares LENSAR Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-19.13 | $5.57 | x |
| 2019-12-31 | $-2.87 | $5.57 | x |
| 2020-12-31 | $6.15 | $5.57 | x |
| 2021-12-31 | $5.85 | $5.57 | x |
| 2022-12-31 | $4.13 | $5.57 | x |
| 2023-12-31 | $4.30 | $5.57 | x |
| 2024-12-31 | $1.62 | $5.57 | x |
| 2025-12-31 | $-2.18 | $5.57 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LENSAR Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -58.66%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-38.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -51.64% | 0.84x | 0.00x | $-10.55 Million |
| 2019 | 0.00% | -48.01% | 0.88x | 0.00x | $-11.60 Million |
| 2020 | -29.42% | -74.95% | 0.33x | 1.18x | $-26.50 Million |
| 2021 | -35.72% | -56.88% | 0.52x | 1.21x | $-25.09 Million |
| 2022 | -47.43% | -56.32% | 0.63x | 1.33x | $-24.11 Million |
| 2023 | -30.49% | -34.11% | 0.61x | 1.48x | $-19.10 Million |
| 2024 | -168.42% | -58.71% | 0.81x | 3.56x | $-33.27 Million |
| 2025 | 0.00% | -58.66% | 0.82x | 0.00x | $-31.68 Million |
Industry Comparison
This section compares LENSAR Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LENSAR Inc (LNSR) | $14.90 Million | 0.00% | 3.67x | $68.43 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About LENSAR Inc
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies des… Read more